Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion
1 other identifier
observational
1,000
1 country
1
Brief Summary
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
December 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 25, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 25, 2024
CompletedFirst Posted
Study publicly available on registry
January 3, 2025
CompletedJanuary 3, 2025
November 1, 2024
7 years
December 25, 2024
January 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response
Age, gender, blood routine (platelet count, neutrophil count, monocyte count, and lymphocyte count), four coagulation tests (prothrombin time determination, activated partial thromboplastin time determination), blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein data), hypertension, diabetes, coronary heart disease, and cerebral infarction were collected in detail Death history, laser, anti-VEGF injection, hormone and other treatment methods and times, and the visual acuity at the last follow-up. The general conditions of the patients were statistically analyzed, such as the proportion of previous history of hypertension and diabetes, and the mean value of blood lipids, blood clotting images and other blood test results of the patients were calculated, and the correlation between them and the prognosis of vision was analyzed.
From January 2024 to January 2025
Study Arms (2)
rvo patients
Initial onset and meeting the diagnostic criteria for RVO (including BRVO and CRVO)
Eligibility Criteria
Patients with RVO diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University from January 2018 to December 2024 were enrolled
You may qualify if:
- meeting the diagnostic criteria for RVO (including BRVO and CRVO)
You may not qualify if:
- patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
- patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
- patients with incomplete clinical data and information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 25, 2024
First Posted
January 3, 2025
Study Start
January 1, 2018
Primary Completion
December 25, 2024
Study Completion
December 25, 2024
Last Updated
January 3, 2025
Record last verified: 2024-11